Assessing subvisible particle risks in monoclonal antibodies: insights from quartz crystal microbalance with

Yibo Wang1, Alexis Hanford1, Mehdi Boroumand2

  • 1Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, USA.

Mabs
|May 12, 2025
PubMed

Related Concept Videos